Medifast Enhances Expansion with Health and Wellness Offerings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2025
0mins
Should l Buy INGR?
Source: NASDAQ.COM
Medifast's Strategic Focus: Medifast, Inc. is enhancing its position in health and wellness by emphasizing personalized support through its OPTAVIA program, which includes one-on-one coaching and tailored nutrition plans.
Expansion of Product Portfolio: The company is broadening its offerings with nutritionally-balanced meals and supplements, while also focusing on areas like hydration, sleep, and mental well-being to redefine itself as a comprehensive health partner.
Technological Enhancements: Medifast is investing in digital tools and apps to improve customer engagement and streamline connections between consumers and their OPTAVIA coaches, aiming for deeper engagement and sustainable growth.
Financial Outlook: Despite a 22.1% decline in shares year-to-date, Medifast is focused on revitalizing its coach and customer base with new products and data-driven support, while the Zacks Consensus Estimate predicts a significant EPS decline for 2025 but growth in 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INGR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INGR
Wall Street analysts forecast INGR stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 112.110
Low
119.00
Averages
125.50
High
136.00
Current: 112.110
Low
119.00
Averages
125.50
High
136.00
About INGR
Ingredion Incorporated is a global ingredient solutions provider serving customers in nearly 120 countries. The Company turns grains, fruits, vegetables and other plant-based materials into value-added ingredient solutions for the food, beverage, animal nutrition, brewing and industrial markets. Its segments include Texture & Healthful Solutions (T&HS), Food & Industrial Ingredients - Latin America (F&II - LATAM) and Food & Industrial Ingredients - U.S./Canada (F&II - U.S./Canada). Its product lines include starches and sweeteners, animal feed products and edible corn oil. Its starch-based products include both food-grade and industrial starches, as well as biomaterials and non-GMO (genetically modified organism) products. Its sweetener products include glucose syrups, high maltose syrups, high fructose corn syrup, caramel color, dextrose, polyols, maltodextrins, glucose and syrup solids, high-intensity sweeteners, and various non-GMO products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jim Cramer's Trust Increases Stake in Cardinal Health
- Increased Stake: Jim Cramer's Charitable Trust purchased 25 shares of Cardinal Health at approximately $210, raising its total holdings to 475 shares and increasing its portfolio weighting from 2.5% to 2.6%, reflecting confidence in the company.
- Market Reaction: Cardinal Health's stock has pulled back about 9% since the onset of the conflict with Iran; however, the company is expected to see earnings per share grow approximately 25% in the current fiscal year, indicating strong profitability amid market volatility.
- Product Growth: Sales of GLP-1 medications have provided a significant tailwind to Cardinal's Pharmaceutical and Specialty Solutions business, contributing 6 percentage points to revenue growth in the most recent quarter, further solidifying its market position.
- Board Changes: The sudden retirement of Chairman Gregory Kenny, replaced by current director Patricia Hemingway Hall, may unsettle investors; however, the company clarified that this decision was not related to operational disagreements and maintains confidence in its future financial outlook.
See More
Ingredion Appoints Interim CFO Jason Payantas Effective April 2026
- Executive Change: Ingredion announced that Jason Payantas will serve as interim Chief Financial Officer starting April 1, 2026, succeeding James D. Gray, who will step down at the end of March, ensuring continuity and stability in financial management.
- Background: Payantas has been with Ingredion since 2012, holding various key positions, most recently as Vice President of Finance for Global Texture & Healthful Solutions since November 2025, demonstrating his extensive experience and capability within the company.
- Financial Outlook: Ingredion anticipates earnings per share in the range of $11 to $11.80 for 2026, indicating confidence in its growth initiatives related to clean label and protein fortification, reflecting a positive outlook on future market demand.
- Strategic Transformation: This executive change aligns with the company's ongoing transformation strategy aimed at enhancing its competitiveness in high-yield and defensive investment sectors, further driving long-term growth.
See More
AI Sparks Potential Blue-Collar Renaissance Amid Job Disruption Fears
- Blue-Collar Employment Revival: Oppenheimer analysts suggest that while AI may rapidly displace white-collar jobs, it could simultaneously drive demand for blue-collar roles, particularly in manufacturing, with employment projected to remain below pre-pandemic levels by 2026.
- Investment Theme Analysis: Oppenheimer outlined five investable themes, including the physical-to-digital connection, emphasizing the value of sensors and data pipelines, with companies in this space expected to benefit from automation trends, including Aeva Technologies and Tesla.
- Automation Tools Opportunity: The analysts identified automation tools that can reskill transitioning workforces, recommending companies like Caterpillar and Rockwell Automation, which enhance worksite experiences through task automation and AI agents.
- Autonomous Systems Development: Oppenheimer also highlighted companies supporting autonomous physical systems, such as Mobileye Global and Aurora Innovation, noting that as fully autonomous solutions are commercialized, human roles will still be essential for remote monitoring and maintenance to ensure safety and problem resolution.
See More
Ingredion Declares $0.82 Quarterly Dividend, Consistent with Previous Payouts
- Quarterly Dividend Announcement: Ingredion has declared a quarterly dividend of $0.82 per share, consistent with previous payouts, indicating the company's stable cash flow and commitment to shareholder returns.
- Dividend Yield: The forward yield of 2.95% reflects the company's attractiveness in the current market environment, potentially drawing in investors seeking stable income.
- Record Date for Shareholders: The dividend will be payable on April 21, with a record date of April 1 and an ex-dividend date also on April 1, ensuring shareholders receive their returns promptly.
- Future Earnings Outlook: Ingredion anticipates earnings per share between $11 and $11.80 in 2026, highlighting the company's growth potential in clean label and protein fortification, which could further enhance its competitive position in the market.
See More
Shiru and Ingredion Announce Global R&D Collaboration
- Collaboration Launch: Shiru and Ingredion have announced a global R&D collaboration aimed at accelerating the discovery and commercialization of novel functional proteins, leveraging Shiru's AI platform that has analyzed over 77 million natural protein sequences, significantly enhancing R&D efficiency.
- Market Demand Response: The partnership focuses on developing next-generation prebiotics derived from natural sources to promote healthier microbiomes, addressing consumer demand for clinically credible and manufacturable ingredients, directly responding to market pressures.
- Wide Customer Reach: Ingredients developed through this joint research will be directed to Ingredion's 18,000+ customers across 120 countries, ensuring that new products can quickly enter the market and enhance customer competitiveness.
- Innovation-Driven Technology: Shiru's AI technology reduces ingredient discovery time from years to months, and combined with Ingredion's market scale and customer relationships, creates a direct path from discovery to market, driving innovation and development in the food industry.
See More
Ingredion CEO James P. Zallie Sells Shares Amid Earnings Concerns
- Share Sale Details: On February 18, 2026, James P. Zallie sold 9,958 shares of Ingredion for approximately $1.16 million, reducing his direct holdings by 23.2% to 33,010 shares, indicating a cautious outlook on the company's future.
- Management Changes: Zallie was appointed Chairman of the Board on February 11, 2026, which may raise investor concerns about governance; however, his share sale was part of a Rule 10b5-1 trading plan, alleviating some worries.
- Lackluster Financial Performance: Despite year-over-year growth in net income and EPS for Q4 of fiscal 2025, Ingredion experienced a revenue decline and has posted three consecutive quarters of declining net income and EPS, highlighting challenges in recovery from global production impacts.
- Investment Considerations: Investors should note that The Motley Fool's analyst team did not include Ingredion in their current top ten stock recommendations, suggesting a cautious market sentiment regarding its future performance, warranting careful risk assessment before investing.
See More
Jim Cramer's Trust Increases Stake in Cardinal Health
- Increased Stake: Jim Cramer's Charitable Trust purchased 25 shares of Cardinal Health at approximately $210, raising its total holdings to 475 shares and increasing its portfolio weighting from 2.5% to 2.6%, reflecting confidence in the company.
- Market Reaction: Cardinal Health's stock has pulled back about 9% since the onset of the conflict with Iran; however, the company is expected to see earnings per share grow approximately 25% in the current fiscal year, indicating strong profitability amid market volatility.
- Product Growth: Sales of GLP-1 medications have provided a significant tailwind to Cardinal's Pharmaceutical and Specialty Solutions business, contributing 6 percentage points to revenue growth in the most recent quarter, further solidifying its market position.
- Board Changes: The sudden retirement of Chairman Gregory Kenny, replaced by current director Patricia Hemingway Hall, may unsettle investors; however, the company clarified that this decision was not related to operational disagreements and maintains confidence in its future financial outlook.
See More
Ingredion Appoints Interim CFO Jason Payantas Effective April 2026
- Executive Change: Ingredion announced that Jason Payantas will serve as interim Chief Financial Officer starting April 1, 2026, succeeding James D. Gray, who will step down at the end of March, ensuring continuity and stability in financial management.
- Background: Payantas has been with Ingredion since 2012, holding various key positions, most recently as Vice President of Finance for Global Texture & Healthful Solutions since November 2025, demonstrating his extensive experience and capability within the company.
- Financial Outlook: Ingredion anticipates earnings per share in the range of $11 to $11.80 for 2026, indicating confidence in its growth initiatives related to clean label and protein fortification, reflecting a positive outlook on future market demand.
- Strategic Transformation: This executive change aligns with the company's ongoing transformation strategy aimed at enhancing its competitiveness in high-yield and defensive investment sectors, further driving long-term growth.
See More
AI Sparks Potential Blue-Collar Renaissance Amid Job Disruption Fears
- Blue-Collar Employment Revival: Oppenheimer analysts suggest that while AI may rapidly displace white-collar jobs, it could simultaneously drive demand for blue-collar roles, particularly in manufacturing, with employment projected to remain below pre-pandemic levels by 2026.
- Investment Theme Analysis: Oppenheimer outlined five investable themes, including the physical-to-digital connection, emphasizing the value of sensors and data pipelines, with companies in this space expected to benefit from automation trends, including Aeva Technologies and Tesla.
- Automation Tools Opportunity: The analysts identified automation tools that can reskill transitioning workforces, recommending companies like Caterpillar and Rockwell Automation, which enhance worksite experiences through task automation and AI agents.
- Autonomous Systems Development: Oppenheimer also highlighted companies supporting autonomous physical systems, such as Mobileye Global and Aurora Innovation, noting that as fully autonomous solutions are commercialized, human roles will still be essential for remote monitoring and maintenance to ensure safety and problem resolution.
See More
Ingredion Declares $0.82 Quarterly Dividend, Consistent with Previous Payouts
- Quarterly Dividend Announcement: Ingredion has declared a quarterly dividend of $0.82 per share, consistent with previous payouts, indicating the company's stable cash flow and commitment to shareholder returns.
- Dividend Yield: The forward yield of 2.95% reflects the company's attractiveness in the current market environment, potentially drawing in investors seeking stable income.
- Record Date for Shareholders: The dividend will be payable on April 21, with a record date of April 1 and an ex-dividend date also on April 1, ensuring shareholders receive their returns promptly.
- Future Earnings Outlook: Ingredion anticipates earnings per share between $11 and $11.80 in 2026, highlighting the company's growth potential in clean label and protein fortification, which could further enhance its competitive position in the market.
See More
Shiru and Ingredion Announce Global R&D Collaboration
- Collaboration Launch: Shiru and Ingredion have announced a global R&D collaboration aimed at accelerating the discovery and commercialization of novel functional proteins, leveraging Shiru's AI platform that has analyzed over 77 million natural protein sequences, significantly enhancing R&D efficiency.
- Market Demand Response: The partnership focuses on developing next-generation prebiotics derived from natural sources to promote healthier microbiomes, addressing consumer demand for clinically credible and manufacturable ingredients, directly responding to market pressures.
- Wide Customer Reach: Ingredients developed through this joint research will be directed to Ingredion's 18,000+ customers across 120 countries, ensuring that new products can quickly enter the market and enhance customer competitiveness.
- Innovation-Driven Technology: Shiru's AI technology reduces ingredient discovery time from years to months, and combined with Ingredion's market scale and customer relationships, creates a direct path from discovery to market, driving innovation and development in the food industry.
See More
Ingredion CEO James P. Zallie Sells Shares Amid Earnings Concerns
- Share Sale Details: On February 18, 2026, James P. Zallie sold 9,958 shares of Ingredion for approximately $1.16 million, reducing his direct holdings by 23.2% to 33,010 shares, indicating a cautious outlook on the company's future.
- Management Changes: Zallie was appointed Chairman of the Board on February 11, 2026, which may raise investor concerns about governance; however, his share sale was part of a Rule 10b5-1 trading plan, alleviating some worries.
- Lackluster Financial Performance: Despite year-over-year growth in net income and EPS for Q4 of fiscal 2025, Ingredion experienced a revenue decline and has posted three consecutive quarters of declining net income and EPS, highlighting challenges in recovery from global production impacts.
- Investment Considerations: Investors should note that The Motley Fool's analyst team did not include Ingredion in their current top ten stock recommendations, suggesting a cautious market sentiment regarding its future performance, warranting careful risk assessment before investing.
See More
